NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

Kemas kini terakhir: 16 jam lalu

69.17

-0.65 (-0.93%)

  • 1H -0.93%
  • 5H 2.17%
  • 1B -7.32%
  • 6B -18.65%
  • Tahun Ke Tarikh -20.97%
  • 1T -51.65%
  • 5T 109.86%
Penutupan Terdahulu 69.82
Buka 69.28
Jumlah Dagangan 4,047,911
Purata Dagangan (3B) 10,334,583
Modal Pasaran 316,353,839,104
Harga / Pendapatan (P/E TTM) 18.64
Harga / Pendapatan (P/E Ke hadapan) 16.61
Harga / Jualan (P/S) 6.43
Harga / Buku (P/B) 14.02
Julat 52 Minggu
57.00 (-17%) — 143.69 (107%)
Tarikh Pendapatan 6 Aug 2025
Hasil Dividen (DY TTM) 2.33%
Margin Keuntungan 34.51%
Margin Operasi (TTM) 49.68%
EPS Cair (TTM) 3.71
Pertumbuhan Hasil Suku Tahunan (YOY) 19.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 14.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 85.70%
Nisbah Semasa (MRQ) 0.740
Aliran Tunai Operasi (OCF TTM) 131.24 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 77.73 B
Pulangan Atas Aset (ROA TTM) 23.29%
Pulangan Atas Ekuiti (ROE TTM) 88.12%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok Novo Nordisk A/S Menurun Menurun

AISkor Stockmoo

-0.4
Konsensus Penganalisis -3.5
Aktiviti Orang Dalam NA
Volatiliti Harga 4.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata -0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
NVO 316 B 2.33% 18.64 14.02
LLY 701 B 0.53% 63.68 44.16
NVS 244 B 3.19% 19.11 6.23
MRK 203 B 2.95% 11.76 4.11
JNJ 375 B 2.38% 17.35 4.81
ABBV 334 B 3.37% 80.54 237.28

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Orang Dalam 0.01%
% Dimiliki oleh Institusi 9.85%

Pemilikan

Nama Tarikh Syer Dipegang
Fayez Sarofim & Co 31 Mar 2025 11,212,499
Everett Harris & Co /Ca/ 31 Mar 2025 6,408,022
174.45174.45131.10131.1087.7587.7544.4044.401.051.05Harga Sasaran MedianQ4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
57.00 (-17%) — 143.69 (107%)
Median 64.00 (-7.47%)
Jumlah 1 Pegang
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
BMO Capital 17 Apr 2025 64.00 (-7.47%) Pegang 58.08
  • 3M
Tarikh Jenis Butiran
28 Jun 2025 Pengumuman HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
26 Jun 2025 Pengumuman Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
23 Jun 2025 CNBC Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
23 Jun 2025 Pengumuman Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
23 Jun 2025 Pengumuman Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
22 Jun 2025 Pengumuman Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
22 Jun 2025 Pengumuman Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
20 Jun 2025 Pengumuman Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
20 Jun 2025 Pengumuman Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
12 Jun 2025 Pengumuman Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
11 Jun 2025 Pengumuman Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
10 Jun 2025 Pengumuman ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
22 May 2025 Pengumuman New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
21 May 2025 CNBC Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
20 May 2025 Pengumuman From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
19 May 2025 CNBC Novo Nordisk is betting on a CEO shake-up to regain its weight loss drug edge over Eli Lilly
16 May 2025 Pengumuman Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
14 May 2025 Pengumuman Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases
12 May 2025 Pengumuman Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
09 May 2025 Pengumuman Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
07 May 2025 Pengumuman Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
01 May 2025 CNBC CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
29 Apr 2025 CNBC Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
25 Apr 2025 CNBC Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
17 Apr 2025 CNBC Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14%
14 Apr 2025 CNBC Pfizer scraps daily weight loss pill after liver injury in one patient
Papar semua
Hasil Dividen (DY TTM) 2.33%
Purata Hasil Dividen 5T 2.48%
Nisbah Pembayaran 47.09%
Jangkaan Pembayaran Dividen Seterusnya Apr 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 Tunai
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 Tunai
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 Tunai
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 Tunai
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 Tunai
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 Tunai
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 Tunai
16 Aug 2021 - 25 Aug 2021 0.5502889 Tunai
26 Mar 2021 - 07 Apr 2021 0.922122 Tunai
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 Tunai
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 Tunai
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 Tunai
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 Tunai
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 Tunai
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 Tunai
17 Aug 2017 - 29 Aug 2017 0.33589 Tunai
23 Mar 2017 - 04 Apr 2017 0.479369 Tunai
11 Aug 2016 - 23 Aug 2016 0.331026 Tunai
18 Mar 2016 - 30 Mar 2016 0.69943 Tunai
19 Mar 2015 - 31 Mar 2015 0.532885 Tunai
21 Mar 2014 - 02 Apr 2014 0.606122 Tunai
21 Mar 2013 - 02 Apr 2013 2.264307 Tunai
22 Mar 2012 - 03 Apr 2012 1.831902 Tunai
24 Mar 2011 - 05 Apr 2011 1.357901 Tunai
25 Mar 2010 - 07 Apr 2010 0.978615 Tunai
19 Mar 2009 - 31 Mar 2009 0.781532 Tunai
13 Mar 2008 - 25 Mar 2008 0.678462 Tunai
08 Mar 2007 - 20 Mar 2007 0.891779 Tunai
09 Mar 2006 - 21 Mar 2006 0.691753 Tunai
10 Mar 2005 - 22 Mar 2005 0.61725 Tunai
17 Mar 2004 - 29 Mar 2004 0.52096 Tunai
26 Mar 2003 - 07 Apr 2003 0.37647 Tunai
13 Mar 2002 - 25 Mar 2002 0.2848 Tunai
21 Mar 2001 - 02 Apr 2001 0.5681 Tunai
24 Mar 2000 - 06 Apr 2000 0.4672 Tunai
25 Mar 1999 - 06 Apr 1999 0.4182 Tunai
27 Mar 1998 - 08 Apr 1998 0.3051 Tunai
25 Apr 1997 - 07 May 1997 0.239 Tunai
01 May 1996 - 14 May 1996 0.1806 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.10 1 1.59
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
Papar semua
74.6874.6871.8471.8469.0069.0066.1666.1663.3263.32Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
3.0003.0002.0002.0001.0001.0000.0000.000-1.000-1.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda